RKDA vs PGEN vs FATE vs SNDX

For growth investors, Syndax Pharmaceuticals, Inc.

(SNDX) is the stronger pick with 627. 8% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Syndax Pharmaceuticals, Inc.

(SNDX) delivered a total return of +28. 1%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: SNDX returned +43. 4% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Syndax Pharmaceuticals, Inc.

(SNDX) is the lower-risk stock at 0. 81β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 169% more volatile than SNDX relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 5% for Syndax Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Syndax Pharmaceuticals, Inc.

(SNDX) is pulling ahead at 627. 8% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -20. 5% for Precigen, Inc.. Over a 3-year CAGR, RKDA leads at -13. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcadia Biosciences, Inc.

(RKDA) is the more profitable company, earning -48. 1% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps -48. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SNDX leads at -158. 4% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — SNDX leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Syndax Pharmaceuticals, Inc.

(SNDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SNDX: +43. 4%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RKDA (Basic Materials) and PGEN (Healthcare) and FATE (Healthcare) and SNDX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RKDA is a small-cap quality compounder stock; PGEN is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; SNDX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.